v3.25.2
Stockholders’ Equity (Tables)
6 Months Ended
Jun. 30, 2025
Equity [Abstract]  
Schedule of Convertible Preferred Stock As of December 31, 2024, the redeemable convertible preferred stock was summarized as follows:
December 31, 2024
(In thousands, except share amounts)Shares Authorized
Shares Issued and Outstanding
Net Carrying Value
Aggregate Liquidation Preference
Series A21,200 21,157 $25,106 $147,647 
Total21,200 21,157 $25,106 $147,647 
Schedule of Reserved Shares of its Common Stock for Future Issuance
The Company had reserved shares of its common stock for future issuance as follows:
June 30,December 31,
20252024
Stock options issued and outstanding4,417,1571,333,030
Restricted stock units outstanding1,097,20956,423
Common stock shares available for future issuance under equity plans2,611,292270,907
Common stock shares available for future issuance under the 2022 Employee Stock Purchase Plan (the “ESPP”)127,68179,387
GeneFab Option1,963,3441,963,344
Warrants to purchase common stock issued in connection with Series A redeemable convertible preferred stock31,735,50031,735,500
Performance stock units outstanding106,806
Unvested early exercised common stock422
Contingent earnout common stock100,000
Common Stock Purchase Agreement484,944
Series A redeemable convertible preferred stock21,157,000
Total41,952,18357,287,763